Michael Lin Baum is an experienced attorney. He was formerly the managing partner at Baum Hedlund Aristei & Goldman, now Wisner Baum. As a lawyer involved in scientific and clinical trials research as it relates to pharmaceutical litigation, Michael Lin Baum has worked on several major mass tort cases involving children and adolescents.

In 2001, over 12 recognized academics published Study 329, a report on the efficacy of Paxil, an antidepressant. However, according to findings, the report was not actually written by medical experts. SmithKline Beecham, also known as GlaxoSmithKline (GSK), the manufacturer of the drug, hired a PR company to ghostwrite the report.

The aim of Study 329 was to convince doctors to prescribe Paxil to adolescents when the Federal Drug Administration (FDA) had not approved it for the pediatric population. It contained falsehoods and was based on unreliable scientific research.

In 2015, in a bid to uphold the efficacy and safety of the drug testing process, an academic research group decided to reanalyze Study 329. Upon reanalysis, the research group concluded that while having almost the same effect as a placebo, Study 329 downplayed the fact that Paxil can cause suicidal tendencies in a significant number of adolescents.